Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 5/20 | 1.00 |
| ▸ | FLT3 | P36888 | 4/20 | 0.66 |
| ▸ | MET | P08581 | 14/20 | 0.65 |
| ▸ | EGFR | P00533 | 4/20 | 0.65 |
| ▸ | KDR | P35968 | 4/20 | 0.65 |
| ▸ | MST1R | Q04912 | 4/20 | 0.65 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.65 |
| ▸ | FLT4 | P35916 | 3/20 | 0.65 |
| ▸ | TEK | Q02763 | 3/20 | 0.65 |
| ▸ | BTK | Q06187 | 3/20 | 0.65 |
| ▸ | SRC | P12931 | 2/20 | 0.65 |
| ▸ | AURKA | O14965 | 2/20 | 0.65 |
| ▸ | LCK | P06239 | 2/20 | 0.65 |
| ▸ | CSF1R | P07333 | 2/20 | 0.65 |
| ▸ | JAK2 | O60674 | 2/20 | 0.65 |
| ▸ | FLT1 | P17948 | 2/20 | 0.65 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.65 |
| ▸ | PLK4 | O00444 | 1/20 | 0.65 |
| ▸ | STK25 | O00506 | 1/20 | 0.65 |
| ▸ | CIT | O14578 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30000966 | 1.00 | AXL (1.00) | AXLFLT3METEGFRKDR | |
| SCHEMBL14289180 | 1.00 | AXL (1.00) | AXLFLT3METEGFRKDR | |
| SCHEMBL1591152 | 0.96 | AXL (0.92) | AXLFLT3METEGFRKDR | |
| SCHEMBL29908856 | 0.96 | AXL (0.92) | AXLFLT3METEGFRKDR | |
| SCHEMBL14289192 | 0.96 | AXL (0.92) | AXLFLT3METEGFRKDR | |
| SCHEMBL15262000 | 0.92 | AXL (0.85) | AXLFLT3METKDRMST1R | |
| SCHEMBL698905 | 0.91 | AXL (0.84) | AXLFLT3METEGFRKDR | |
| SCHEMBL1554813 | 0.91 | AXL (0.84) | AXLMET | |
| SCHEMBL13896124 | 0.90 | AXL (0.82) | AXLFLT3METEGFRKDR | |
| SCHEMBL30465532 | 0.90 | AXL (0.81) | AXLFLT3METEGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462117-B1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2017-06-28 | — | — | EP | claimed |
| EP-2780338-B1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA INC (US) | 2016-11-09 | — | — | EP | claimed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | claimed |
| US-9169241-B2 | Quinolinyloxyphenylsulfonamides | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-10-27 | — | — | US | claimed |
| US-20140336191-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2014-11-13 | — | — | US | claimed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-20120277231-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-11-01 | — | — | US | claimed |
| EP-2262772-B1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2012-07-18 | — | — | EP | claimed |
| EP-2462117-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-06-13 | — | — | EP | claimed |
| EP-2262772-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2010-12-22 | — | — | EP | claimed |
| WO-2009127417-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-10-22 | — | — | WO | claimed |
| EP-3810596-B1 | QUINOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-11-30 | — | — | EP | disclosed |
| CN-112351971-B | Quinoline or quinazoline compound and application thereof | 上海海和药物研究开发股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-3778585-B1 | QUINOLINE OR QUINAZOLINE COMPOUND AND APPLICATION THEREOF | HAIHE BIOPHARMA CO LTD (CN) | 2022-10-19 | — | — | EP | disclosed |
| US-20220089541-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2022-03-24 | — | — | US | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20060235033-A1 | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-10-19 | — | — | US | disclosed |
| EP-1535910-A1 | QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20040242603-A1 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1411046-A1 | QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF−PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2004-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336191-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | TP53, AQP1, KRAS | AXL 4326/4885FLT3 1584/4885MET 2187/4885 |
| US-20120277231-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | TP53, AQP1, KRAS | AXL 4326/4885FLT3 1584/4885MET 2187/4885 |
| US-20040242603-A1 | Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor and medicinal composition containing the same | NR1H2, NR1H3, NR1H4 | AXL 1853/4885FLT3 134/4885MET 72/4885 |
| US-20060235033-A1 | Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor | CSF3R, CSF1R, MSR1 | AXL 164/4885FLT3 4/4885MET 26/4885 |
| US-20220089541-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | PRKDC, MAP3K20, BRAF | AXL 1643/4885FLT3 470/4885MET 367/4885 |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | AXL 1/4885FLT3 4/4885MET 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.